Literature DB >> 15331349

Recent advances in alcoholic liver disease. IV. Dysregulated cytokine metabolism in alcoholic liver disease.

Craig J McClain1, Zhenyuan Song, Shirish S Barve, Daniell B Hill, Ion Deaciuc.   

Abstract

Alcoholic liver disease (ALD) remains a leading cause of death from liver disease in the United States for which there is no FDA-approved therapy. Abnormal cytokine metabolism is a major feature of ALD. Elevated serum concentration levels of TNF-alpha and TNF-alpha-inducible cytokines/chemokines, such as IL-6, -8, and -18, have been reported in patients with alcoholic hepatitis and/or cirrhosis, and levels correlated with markers of the acute phase response, liver function, and clinical outcome. Studies in animal models support an etiologic role for cytokines in the liver injury of ALD. Cytokines, such as transforming growth factor-beta, play a critical role in the fibrosis of ALD. Multiple new strategies are under investigation to modulate cytokine metabolism as a form of therapy for ALD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15331349     DOI: 10.1152/ajpgi.00171.2004

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  79 in total

1.  Estrogen suppresses heptatic IκB expression during short-term alcohol exposure.

Authors:  Eric G Lee; Bethany M Mickle-Kawar; Lester A Reinke; Randle M Gallucci
Journal:  Inflamm Res       Date:  2012-06-06       Impact factor: 4.575

Review 2.  Clinical implications of oxidative stress and antioxidant therapy.

Authors:  Gerald W Dryden; Ion Deaciuc; Gavin Arteel; Craig J McClain
Journal:  Curr Gastroenterol Rep       Date:  2005-08

Review 3.  Alcoholic liver disease and malnutrition.

Authors:  Craig J McClain; Shirish S Barve; Ashutosh Barve; Luis Marsano
Journal:  Alcohol Clin Exp Res       Date:  2011-02-01       Impact factor: 3.455

4.  Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8.

Authors:  Ahmed Abu Shanab; Paul Scully; Orla Crosbie; Martin Buckley; Liam O'Mahony; Fergus Shanahan; Sanaa Gazareen; Eileen Murphy; Eamonn M M Quigley
Journal:  Dig Dis Sci       Date:  2010-11-03       Impact factor: 3.199

5.  Advanced periductal fibrosis from infection with the carcinogenic human liver fluke Opisthorchis viverrini correlates with elevated levels of interleukin-6.

Authors:  Banchob Sripa; Eimorn Mairiang; Bandit Thinkhamrop; Thewarach Laha; Sasithorn Kaewkes; Paiboon Sithithaworn; Smarn Tessana; Alex Loukas; Paul J Brindley; Jeffrey M Bethony
Journal:  Hepatology       Date:  2009-10       Impact factor: 17.425

6.  Definition, epidemiology and magnitude of alcoholic hepatitis.

Authors:  Sarpreet Basra; Bhupinderjit S Anand
Journal:  World J Hepatol       Date:  2011-05-27

7.  Nuclear factor-kappaB1 (p50) limits the inflammatory and fibrogenic responses to chronic injury.

Authors:  Fiona Oakley; Jelena Mann; Sarah Nailard; David E Smart; Narendra Mungalsingh; Christothea Constandinou; Shakir Ali; Susan J Wilson; Harry Millward-Sadler; John P Iredale; Derek A Mann
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

8.  Alterations in Serum Zinc and Polyunsaturated Fatty Acid Concentrations in Treatment-Naive HIV-Diagnosed Alcohol-Dependent Subjects with Liver Injury.

Authors:  Vatsalya Vatsalya; Matthew C Cave; Rajarshi Kumar; Shweta Srivastava; Sujita Khanal; Alfred B Jenson; Melanie L Schwandt; Shirish S Barve; Vijay A Ramchandani; Craig J McClain
Journal:  AIDS Res Hum Retroviruses       Date:  2018-12-11       Impact factor: 2.205

9.  Tumor necrosis factor antagonism normalizes rapid eye movement sleep in alcohol dependence.

Authors:  Michael R Irwin; Richard Olmstead; Edwin M Valladares; Elizabeth Crabb Breen; Cindy L Ehlers
Journal:  Biol Psychiatry       Date:  2009-01-29       Impact factor: 13.382

Review 10.  Alcohol and lipid metabolism.

Authors:  Margaret Sozio; David W Crabb
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-03-18       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.